Company: SCLXW
Filing Date: 2025-11-14
Form Type: 424B3
Source: 0001193125-25-283322
Chunk: 99

Company: Scilex Holding Co
Filing Date: 2025-11-14
Form: 424B3
Chunk 99
---
 additional expenses related to KDS2010 to Scilex Bio. Selling, General and Administrative Expenses Selling, general and administrative expenses for the nine months ended September 30, 2025 and 2024 were $236.7 million and $83.6 million, respectively. The increase of approximately $153.1 million was primarily due to a $140.0 million increase related to issuance costs for reverse recapitalization with Denali, a $23.7 million increase in advisory and financing expenses, a $3.4 million increase in contracted services, a $1.8 million increase related to issuance costs for September 2025 Warrants, a $3.0 million increase in expense related to the shares of Common Stock issuable to Tumim in connection with the Company’s equity line of credit with Tumim and a $1.1 million increase in other expenses, partially offset by a $5.5 million decrease in rebate expenses primarily related to future shipments of the Additional Product (as defined in the Satisfaction Agreement) under the Satisfaction Agreement, a $4.8 million decrease in marketing expenses, a $4.7 million decrease in personnel expense, a $2.9 million decrease in travel expenses, a $1.2 million decrease in allowances for expected credit losses on accounts receivable, a $0.7 million decrease in insurance costs and a $0.1 million increase in legal fees in the nine months ended September 30, 2025. Intangible Amortization Expense Intangible amortization expense for each of the nine months ended September 30, 2025 and 2024 was $3.0 million. Legal Settlements Legal settlements for the nine months ended September 30, 2025 and 2024 were $0.1 million and $9.4 million, respectively. The $9.3 million change was attributed to payments received in the amount of $9.4 million from litigation settlements that were entered into during the first quarter of 2024, offset by $0.1 million payments made for a litigation settlement that was entered into during the second quarter of 2025, the terms of which are confidential. See Note 12 titled “ Commitments and Contingencies ” to our consolidated financial statements in our Annual Report on Form 10-K and Note 11 titled “ Commitments and Contingencies ” to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Loss (gain) on Derivative Liability